{"name":"NLS Pharmaceutics","slug":"nls-pharmaceutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NLS-2","genericName":"NLS-2","slug":"nls-2","indication":"Narcolepsy type 1 and type 2","status":"phase_3"}]}],"pipeline":[{"name":"NLS-2","genericName":"NLS-2","slug":"nls-2","phase":"phase_3","mechanism":"NLS-2 is a selective orexin-2 receptor agonist that promotes wakefulness by enhancing neural signaling in brain regions responsible for arousal and alertness.","indications":["Narcolepsy type 1 and type 2","Excessive daytime sleepiness"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9GZW1kVG9INFFwSjJmZlExWVJmRU1pUFFwQ19pNVk1T251STMtM29ETDlPRzNrd2lnTkFoVm9lQldaVDh2eHR5LXdBTGxtYkFLV3FEU0FBc3B1dw?oc=5","date":"2025-11-05","type":"pipeline","source":"MarketBeat","summary":"NLS Pharmaceutics (NCEL) Stock Price, News & Analysis - MarketBeat","headline":"NLS Pharmaceutics (NCEL) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNMXNEcVRQRlF1RGVzVnZOVzhpV01tRTI5U3BxNlNYaW53NFFmZDR0cG1haXNLbTAyUTA3RHdleWlPeGU4NHE3WjFndFJPYXNhUTVFT1o3aVl6T050NXFHVXBtdEQxMFVlMndlRGc3MTIway1VMlRNN2tuVDhMOUlSMEMtMUJ2SWRaZERJbTV5WENzVFEwS3lJ?oc=5","date":"2025-11-04","type":"pipeline","source":"startupticker.ch","summary":"NLS Pharma and Kadimastem finalise business combination - startupticker.ch","headline":"NLS Pharma and Kadimastem finalise business combination","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQcXc4TWl1M29nTnAzTG1rMzk3N2pQNlhVYXQwdW1ZWHBuX0dweWhmVlU5U0tPenpLT1BCblItY01iQUNXOF9qR182X0FTSl9CUTJhMjJJbVZsZ0hQNWx2SGxNSGVkZjJiTkxlQzlmNFluQXptT09mRlgwSjY2aVM1SElGeWp0eF95XzRUOEdTejFsMlZYeHprMV9oMy04X201NlJ6TUhBdUtSY0FuZTN0VGIxMk1yTzFvY3pDZ2VHSlNmd3JWd1pIRzdMQ0hqUmFCUkxiXw?oc=5","date":"2025-10-30","type":"pipeline","source":"prnewswire.com","summary":"NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs - prnewswire.com","headline":"NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxOY2I1ZDR4N2M1VnZEWFAxOWRMMXdIbEJyZnFvZ29kekJ3akZsYWR5bHB0R2dXTzVfV1cya3JKUVR5NDM0ZmdfRUxWTG9weURuNnp4MTBCb19SZFJIVTd0S2std21heGx4dkg1aFgwVEVJMDVxZjQ3RWM5ZHpHWkVZVnk1U2dfbXo4QUpNM0J3dkhrcmttLU1wdE1vWUFFOGQ3TTFzSUZJNEVNc0M5THpxN1QtQjI3WjNOUjNWVVY2YW8wcGJHa0p0NXhrMlZNQmVGOTFLNDNBMEZWR0Z1NWdqQVR0Zm9Lc09NazlWSXB3VW5RUDBPcWhGa0VQaFBncHU2VVh0bUQxZTlCWGVPaDEtQw?oc=5","date":"2025-10-29","type":"deal","source":"prnewswire.com","summary":"NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem - prnewswire.com","headline":"NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Ka","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxPcUFLMlJjb1E4UlhuWkV2TzkyMWFma1BOZlRuQUNJYjBtQjJnOS1MajN2REVGRnVUSExhbUlqMHM4MERBQ3pEbGdNeEJnZVJYNVZONDZPeU9WcFhQdng1OEM5MEUxb3l1am4zUGxBcG02QllFazFxb09YUmRnOTR3c1RMcFdWRW5aWWNwcll0Ql91eGphX1Q0ekpfMUdDNEFNdjNLcWhmbjByeV9LMWgwelJqTkRJWks1MHFxalQxYkFYTjBBbW5scm0wY04xLWpoM1NkSjlfeEJQY2wtM1NhNXFtdVF2ZHZIZVhPRjU2aEVOME5kR183TE5VOE9PeVpOajBvaWhfWExSR1NGc2V1V1ZKMVp2SzJvT2doUG9Sb3FIVURwNjFWclNVOFB4Zw?oc=5","date":"2025-10-29","type":"deal","source":"prnewswire.com","summary":"NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares - prnewswire.com","headline":"NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPemNLZUloMnY1akxkRzRuUmk0MjdzZXVTS1NndE9DUUx6M3NzT2ZMd2ZzR2U0Q1ZubXdDY2RIc1JOTnZCdFRDSy1YLUpfM2hXb3RKNnh2M1lGNEpaNnpXVXEyZ1NSMm1VQjZUZ1BoMkQ1QWVVXzc5Zl8wdVNKaTZnVm54NEFVSXhXUXVmM1IyektyZVI4U3VEZDF0cjV5eFdQdkRWTERNSUpVR1VNYTRsU0JVVGtTakwxTXRNZnAxWEF1YlBqREtTemw5SjZQd1haU3BzZDNDb0dKMXl3eTFfX1JWMXN0a0Q2cGY4czkzR3FkeEY0NWxhalFjZ0RZTFNwWUZQUlIzVUNEeVU?oc=5","date":"2025-10-29","type":"deal","source":"prnewswire.com","summary":"NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger - prnewswire.com","headline":"NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Mer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOZ0Fkd241TDFGTGthbG1rWkFfY0RteG5fRHpEdGxRSGVmX0tPVTNpR0FqYlhhOFJFN3JGQlpwTVJ3UlVVek1MRUtEVER1a1VsMFB5V25rOGtIRnhNNm5TYXdjbkVXQjlHMS03ckpLeUxFb29aLXo3OFdjSkNZTVprSmFCUS05amlmcGlGd2pQWXVtVV9RdnlMSy0zeWdCWXRqNGY1OVJPbnZiX1F4dUdzaGo3YUhhRElSVmgtZmRIaHNkWmEtRDRXWTZ5NDFZRF93VUxCdnRENDM1X3F3bjNTNElnNDZaS3AyTGpFeVhnVW9yRTFYS0NLb0MwWmwxNFZzcWNOb3MxandXcldHZ20tQm8xLVJFVDBOVU1jMEh0ckFGNnRzRTJUSU9acTlRa1pMZXI4?oc=5","date":"2025-10-27","type":"deal","source":"prnewswire.com","summary":"NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies - prnewswire.com","headline":"NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Gene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOYlNmY2I0eVVQY1YzRGE0TVhSRHVkZmdvRXhOQzBTUmpEWUM4Wk5CU3RKUkExYTRGZzltdVU5U0xKaTd1OFNtaHkzLTZ6RUJLUDR4TEZhYW5IckJHWmFaS3RDaVJqNWZvV096b2dVVTVOV09oUURpakpiVTROd2N2Nnlqc0J2cVFxQkc1cjhrZlAzSU5lejNhMXVPQkRvbl8xeFdlb3ZKWkplUEE5bTBUazZEWkhCdFg0VzIzeUE0TnVuRmx5bC13Y2ZjUHBrUUdSeXFLRmIxTHV0M1Q1bjA0dE1Uc0Z6dk1GY2c?oc=5","date":"2025-10-23","type":"regulatory","source":"prnewswire.com","summary":"NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 - prnewswire.com","headline":"NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxOMW16Vk1CaWJjNXJrRUd2MDcydGNZVjdaTFBoTkJURmdmaHd2cmM5NUVvRC1HQUtaMjV0QUxwSi13bnEtXzd4YWEwOWQxNDVRbkFzdUtHc1YyWFZiOUQweEZ1c2s3RndkMEh5aWFMeWkyc3pZTDhtYnJJOW5ockludU5PWThoeWpKaEdqS3IxWGFJcFNudFM4ZlhJbWFUM1ZtTW9HUWplemdTVnh3VEtCcG0yVVcwMHNQUGF3VHczVnd5ZEZYdmJCNXlfTU9kQThtLUttX25TRlNqX3Zuc3AtLTBKdHRLTGRsV1pOU2pBeU8wQjhFMkZOek9BYmFmUUxhdlE?oc=5","date":"2025-09-30","type":"regulatory","source":"prnewswire.com","summary":"NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting - prnewswire.com","headline":"NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQZzVGdE5BVFJPY0dmODJQUkNNMFhZMDFWVVYtNnczNnQyRGlQS0FBUDE1b3pWdzFQVHVCZ1huWmlzQmk2M2lHeTBiQTBMMEZNdnVyNUsxX0ctQ3hJVlBDU1J2RUFkOFdrdUlqbVdEVXQyOHNQeGJkNTFvQXlJdGpNdFdUcnFaWGppcncxUk9fRkxmSFFNc19LY2MwUEpleDczU1VkSXpxX0R4dnk0MXBsaGJUZVA3dFluSHUwN0dEdTNfUTZ4clZuYmRabGZ2QmFZOUMySl9PaFZYaGpmVzBqRHd0WUowaWM3bWhabmpTNUF6ZWJILWFBUERaUjlUdWNsTHFMbFY0aw?oc=5","date":"2025-09-10","type":"deal","source":"prnewswire.com","summary":"Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger - prnewswire.com","headline":"Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOR0FtY2FrS3dreXpNb3g0SFVPQjFtQkxUaGNwS0hqdTVJbFYyX29qb1gtejBSM25QazM3TU4zOHo4OUJhWTNaSkFLbEV5cER2WWJXRzZDdmRqNDE4cmNMMmExMnBJNGZQNnNrdnhaallyUHpORGxSb2lQaFN4NnFES3huOUs1MVVHWk43bG16UGlsQlhpal9hTA?oc=5","date":"2025-06-16","type":"deal","source":"Stock Titan","summary":"NLS Pharmaceutics Transforms: $25M Backing Powers Merger Deal as Company Goes Debt-Free - Stock Titan","headline":"NLS Pharmaceutics Transforms: $25M Backing Powers Merger Deal as Company Goes Debt-Free","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQWUkzRnNXeVY5bzBBNnRzQi01RzVDeERnZVJ3ZV9scGNaVlZqeFR3RVhDYlBUVk5vOUhycWRJa08tUjBHN2dFRzJvZUttNllvOWFvV1J2Tnp0YzhoVnFSa2lLdjBZLUFCM1kxLXAtVDN6UWRyaDNDZ3BteWxabFhqU2c2VXM3a1JnM2xSa3FGa2QxTlVNYVJxOU9jUVVLQnR3Q3pNYmloM1VFTC1feUQyZmZQdw?oc=5","date":"2024-11-05","type":"deal","source":"BioSpace","summary":"NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - BioSpace","headline":"NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}